Tisagenlecleucel (Kymriah®) for the treatment of paediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||19/09/2018|
|Rapid review completed||19/10/2018|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tisagenlecleucel compared with the current standard of care.|